{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T14:40:22Z","timestamp":1769352022487,"version":"3.49.0"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This is the English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors (JAK1 and tyrosine kinase 2 [TYK2] inhibitors) in the treatments of psoriasis. Several cytokines, such as interleukin (IL)\u20106, IL\u20107, IL\u201012, IL\u201021, IL\u201022, IL\u201023, interferon (IFN)\u2010\u03b1, and IFN\u2010\u03b3, are involved in the pathogenesis of psoriasis (including psoriatic arthritis). As oral JAK inhibitors hinder the JAK\u2010signal transducers and activators of transcription signal transduction routes involved in the signal transduction of these cytokines, they may be effective for the treatment of psoriasis. JAK has four types: JAK1, JAK2, JAK3, and TYK2. Regarding the use of oral JAK inhibitors for the treatment of psoriasis in Japan, indications of the JAK1 inhibitor upadacitinib were extended also to psoriatic arthritis in 2021, and the use of the TYK2 inhibitor deucravacitinib for plaque\u2010type psoriasis, pustular psoriasis, and erythrodermic psoriasis became covered by health insurance in 2022. This guidance was developed for board\u2010certified dermatologists who specialize in the treatment of psoriasis and to promote the proper use of oral JAK inhibitors. In the package inserts and guides for appropriate use, upadacitinib and deucravacitinib are classified as a \u201cJAK inhibitor\u201d and a \u201cTYK2 inhibitor\u201d, respectively, and it is possible that there may be differences in safety between the two drugs. The safety of these drugs will be evaluated for the future by the postmarketing surveillance for molecularly targeted drugs for psoriasis of the Japanese Dermatological Association.<\/jats:p>","DOI":"10.1111\/1346-8138.16797","type":"journal-article","created":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T09:31:05Z","timestamp":1680341465000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["English version of Japanese guidance for the use of oral Janus kinase inhibitors (<scp>JAK1<\/scp> and <scp>TYK2<\/scp> inhibitors) in the treatments of psoriasis"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"first","affiliation":[{"name":"Department of Dermatology Nippon Medical School  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Mabuchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tokai University School of Medicine  Isehara Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3182","authenticated-orcid":false,"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Abe","sequence":"additional","affiliation":[{"name":"Kojinkai Sapporo Skin Clinic  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuyuki","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology NTT Medical Center Tokyo  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Faculty of Medicine Fukuoka University  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-1259","authenticated-orcid":false,"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Dermatology Tokyo Medical University  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1086-1803","authenticated-orcid":false,"given":"Mayumi","family":"Komine","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jichi Medical University  Shimotsuke Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of the Ryukyus Graduate School of Medicine  Okinawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-3033","authenticated-orcid":false,"given":"Hideshi","family":"Torii","sequence":"additional","affiliation":[{"name":"Division of Dermatology Tokyo Yamate Medical Center  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yotsuyanagi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases Advanced Clinical Research Center Institute of Medical Science The University of Tokyo  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Research Division for Development of Anti\u2010Infective Agents Faculty of Medical Science and Welfare Tohoku Bunka Gakuen University  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jichi Medical University  Shimotsuke Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Committee for reviewing the safety of molecularly targeted drugs for psoriasis, Japanese Dermatological Association","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/e7ayu8"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0096"},{"key":"e_1_2_10_5_1","unstructured":"AbbVieGK.Package inserts Rinvoq\u00ae (upadacitinib hydrate) tablets. (Revised May 2022). [cited 2022 November 14]. Available from:https:\/\/www.info.pmda.go.jp\/go\/pack\/3999048G2024_1_09\/(in Japanese)"},{"key":"e_1_2_10_6_1","unstructured":"Bristol\u2010Myers SquibbKK.Package inserts Sotyktu\u00ae (Deucravacitinib) tablets. (Created September 2022). [cited 2022 November 14]. Available from:https:\/\/file.bmshealthcare.jp\/bmshealthcare\/pdf\/package\/Tyk2.pdf?date=20221018(in Japanese)"},{"key":"e_1_2_10_7_1","unstructured":"AbbVieGK.Guide for the proper use of Janus kinase (JAK) inhibitor Rinvoq\u00ae (upadacitinib hydrate) tablets. (Created May 2022). [cited 2022 November 14]. Available from:https:\/\/a\u2010connect.abbvie.co.jp\/\u2010\/media\/assets\/pdf\/products\/rinvoq\/RINVOQ_useguide.pdf(in Japanese)"},{"key":"e_1_2_10_8_1","unstructured":"Bristol\u2010Myers SquibbKK.Guide for the proper use of Sotyktu\u00ae (Deucravacitinib) tablets. (Created September 2022). [cited 2022 November 14]. Available from:https:\/\/file.bmshealthcare.jp\/bmshealthcare\/pdf\/guide\/Tyk2\u2010guide.pdf?date=20221018(in Japanese)"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non\u2010biological therapy: 56\u2010week data from the phase 3 SELECT\u2010PsA 1 study","volume":"7","author":"Mclnnes IB","year":"2021","journal-title":"RMD Open"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00305-z"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2017.01.002"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13503"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-009-0197-6"},{"key":"e_1_2_10_18_1","volume-title":"Japan College of Rheumatology\/guideline committee for RA therapeutic medicine: guidance for the use of TNF inhibitors for rheumatoid arthritis (RA)","author":"Guideline Committee"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16691"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218398"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209773"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.16797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:32:13Z","timestamp":1692707533000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.16797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/1346-8138.16797"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.16797","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2023-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}